2023 World Conference on Lung Cancer (Posters)-EP11.03. Real World Experience of First Line Pembrolizumab for Non-Small Cell Lung Cancer (NSCLC) at a Tertiary Centre

EP11.03. Real World Experience of First Line Pembrolizumab for Non-Small Cell Lung Cancer (NSCLC) at a Tertiary Centre - PDF(Slides)

Back to course

Pdf Summary

This study examines the real-world experience of using pembrolizumab as a first-line treatment for non-small cell lung cancer (NSCLC) at a tertiary center. The researchers analyzed data from patients who were prescribed pembrolizumab between January 2016 and March 2023 and had PD-L1 tumor proportion scores (TPS) of 1% or higher. They also evaluated the Lung Immune Prognostic Index (LIPI), a clinical prognostic factor based on baseline blood markers. The results showed that patients with good performance had survival outcomes comparable to those in the KEYNOTE-042 trial, which demonstrated the efficacy of pembrolizumab compared to chemotherapy. However, LIPI scores were not associated with improved overall survival (OS), although the study was limited by the small number of patients in the LIPI poor cohort and its retrospective design. The median OS was 16.0 months, and the median progression-free survival (PFS) was 7.1 months. Baseline patient characteristics were also analyzed, including age, sex, smoking status, histology, PD-L1 TPS, and LIPI score. The study adds to the understanding of the use of pembrolizumab in real-world settings and its correlation with patient outcomes. Further research is needed to validate these findings and explore the potential of LIPI as a prognostic factor for immunotherapy response in NSCLC patients.

Asset Subtitle

William Mullally

Meta Tag

Speaker William Mullally

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

pembrolizumab

first-line treatment

non-small cell lung cancer

NSCLC

tertiary center

PD-L1 tumor proportion scores

Lung Immune Prognostic Index

overall survival

progression-free survival

baseline patient characteristics